Skip to content

Periodontal tissue regeneration using frozen PRP.

Safety evaluation of periodontal tissue regeneration using frozen PRP. - Periodontal tissue regeneration using frozen PRP.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030220694
Enrollment
3
Registered
2023-03-10
Start date
2024-05-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Interventions

Sponsors

Tobita Morikuni
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Have a Periodontal pocket more than 5 mm at baseline examination. 2) Intrabony defect is 5 mm and more depth, and 2 mm and more width at interproximal site of the experimental tooth by X-ray examination. 3) Already have received initial preparation at the screening. 4) Hized gingiva and for whom flap surgery is deemed appropriate. 5) Persons whose oral hygiene is established Good oral hygiene. 6) 18 years and older. 7) Signed informed consent 8) The principal investigator believes makes him/her suitable for participation in this clinical study.

Exclusion criteria

Exclusion criteria: 1) Can not be measured clinical attachment level of experimental tooth. 2) Have a history of Complicate malignant tumor. 3) Suspected of oral malignant tumor or precancerous lesion. 4) Need to undergo the treatment, such as surgical treatment, restorative treatment or root canal treatment, at the experimental tooth within 36 weeks after transplant. 5) Pregnancy, during breastfeeding, or possibility of pregnancy. 6) Persons who suffer from disorders of kidney, liver or blood 7) Have disease of kidney, liver and/or blood. 8) Have active infectious diseases. 9) Alcoholism or Drug dependence. 10) Mental or consciousness disorder. 11) HCV antibody, HBs antigen, ATLA virus antibody or HIV antibody positive person. 12) Smoke more than 10 pieces per day. 13) Have anti-coagulant or anti-platelet medications, or have a bleeding disorders. 14) Other,the investigator believes makes him/her unsuitable for participation in the clinical study.

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Efficacy

Countries

Japan

Contacts

Public ContactMika Iguchi

Juntendo university

m.iguchi.vm@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026